17 / 38
Median PFS, months (95% CI)
15.2 (12.1, 24.4)
9.6 (7.0, 12.4)
0.2
0.4
0.6
0.8
1.0
0.0
0
3
6
9
12
15
18
21
24
27
Time from randomisation (months)
53
63
51
57
40
40
37
33
32
24
22
13
9
6
4
2
1
1
0
0
Probability of progression-free survival
No. at risk
Osimertinib
SoC
Osimertinib
SoC
FLAURA: PFS in patients with/without CNS mts
re
With CNS metastases (n=116)
Without CNS metastases (n=440)
0.2
0.4
0.6
0.8
1.0
0.0
0
3
6
9
12
15
18
21
24
27
Time from randomisation (months)
226
214
211
182
193
157
173
119
146
83
117
65
62
31
22
8
3
1
0
0
Osimertinib
SoC
CNS progression events occurred in 17 (6%) vs 42 (15%) patients receiving osimertinib vs SoC (all patients)
Median PFS, months (95% CI)
19.1 (15.2, 23.5)
10.9 (9.6, 12.3)
HR 0.47
(95% CI 0.30, 0.74)
p=0.0009
HR 0.46
(95% CI 0.36, 0.59)
p<0.0001
Osimertinib
SoC
Ramalingam et al ESMO 2017 #LBA2; Soria NEJM 2017